What is Viridian Therapeutics Financial Strength?
Viridian Therapeutics has the Financial Strength Rank of 7.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Viridian Therapeutics did not have earnings to cover the interest expense.
Viridian Therapeutics's debt to revenue ratio for the quarter that ended in Dec. 2023 was 73.08.
As of today, Viridian Therapeutics's Altman Z-Score is 7.60.
Competitive Comparison of Viridian Therapeutics's Financial Strength
For the Biotechnology subindustry, Viridian Therapeutics's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viridian Therapeutics's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viridian Therapeutics's Financial Strength distribution charts can be found below:
* The bar in red indicates where Viridian Therapeutics's Financial Strength falls into.
Viridian Therapeutics Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Viridian Therapeutics's Interest Expense for the
months ended in Dec. 2023 was $-0.92 Mil. Its Operating Income for the
months ended in Dec. 2023 was $-71.48 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $20.21 Mil.
Viridian Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is
| Viridian Therapeutics did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Viridian Therapeutics's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Viridian Therapeutics has a Z-score of 7.60, indicating it is in Safe Zones. This implies the Z-Score is strong.
Good Sign:
Altman Z-score of 7.6 is strong.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viridian Therapeutics (Viridian Therapeutics) Business Description
Traded in Other Exchanges
Address
221 Crescent Street, Suite 401, Waltham, MA, USA, 02453
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
Executives
| Stephen F. Mahoney |
director, officer: President and CEO |
C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
| Thomas W. Beetham |
officer: Chief Operating Officer |
C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
| Sarah Gheuens |
director |
C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139 |
| Seth Harmon |
officer: See Remarks |
C/O VIRIDIAN THERAPEUTICS, INC., 221 CRESCENT STREET, SUITE 401, WALTHAM MA 02453 |
| Lara Meisner |
officer: General Counsel and Secretary |
C/O VIRIDIAN THERAPEUTICS, INC., 203 CRESCENT STREET, BLDG. 17, SUITE 102, WALTHAM MA 02453 |
| Scott Dunseth Myers |
director, officer: Chief Executive Officer |
C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121 |
| Jonathan Violin |
officer: President and COO |
955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087 |
| Barrett Katz |
officer: Chief Medical Officer |
6200 LOOKOUT ROAD, C/O MIRAGEN THERAPEUTICS, INC., BOULDER CO 80301 |
| Fairmount Healthcare Fund Gp Llc |
director, other: See Remarks |
2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103 |
| Carrie Melvin |
officer: COO |
C/O VIRIDIAN THERAPEUTICS, INC., 203 CRESCENT STREET, BLDG 17, SUITE 102B, WALTHAM MA 02453 |
| Frazier Life Sciences Public Fund, L.p. |
10 percent owner |
TWO UNION SQUARE, 601 UNION ST., SUITE 3200, SEATTLE WA 98101 |
| L.p. Fhmlsp, |
10 percent owner |
C/O FRAZIER HEALTHCARE PARTNERS, 601 UNION STREET, SUITE 3200, SEATTLE WA 98101 |
| Fhmlsp, L.l.c. |
10 percent owner |
C/O FRAZIER HEALTHCARE PARTNERS, 601 UNION STREET, SUITE 3200, SEATTLE WA 98101 |
| Kristian Humer |
officer: CFO and CBO |
C/O VIRIDIAN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER CO 80301 |
| Jennifer K. Moses |
director |
79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709 |
Viridian Therapeutics (Viridian Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VRDN has been successfully added to your